High-end preparations are an important direction for pharmaceutical enterprises to innovate, and the construction of industrialization bases in this field is "in full swing"

【Pharmaceutical Network Market Analysis】Recently, the high-end chemical preparation industrial park project of Lianyungang Economic and Technological Development Zone successfully passed the completion acceptance
.
The high-end chemical preparation industrial park is an important part of the core area of China Medicine Port, with a total investment of about 1.
2 billion yuan and a total construction area of 265,000 square meters
.
After the completion of the project, it will be mainly used as a production base for high-end chemical preparations, high-end medical devices and biological materials, which will provide a new carrier
for attracting investment in the pharmaceutical sector in the development zone.
High-end preparations become an important direction for pharmaceutical enterprises to innovate, and pharmaceutical enterprises will welcome the good (Image source: Pharmaceutical Network) In February this year, Jiudian Pharmaceutical's high-end preparation R&D industrial park located in Liuyang Economic Development Zone also began construction
.
The project is a one-stop innovative service project for high-end preparation CDMO, focusing on national pharmaceutical enterprises in preparation to reduce R&D and manufacturing costs, improve the efficiency and success rate of innovative drug transformation, shorten the time to market of drugs, and provide one-stop CDMO innovation services
including design and development, small-scale trials, pilot scale-up, process verification, preclinical research, registration application and customized production.
At present, the project has entered the end and is expected to be put into trial production
by the end of the year.
After the project is fully put into operation, it is expected that the annual output value will reach 6 billion yuan, and the annual profit and tax will be more than
800 million yuan.
For all localities and pharmaceutical companies are vigorously building high-end preparation R&D industrial park projects, the industry believes that this will further optimize the production process of foreign enterprises' preparation products, reduce production costs, improve product quality and performance, enhance the core competitiveness of enterprises, and promote the rapid development
of enterprises.
At the same time, it will also have a positive impact
on promoting local employment and tax revenue.
In fact, in the centralized procurement environment, as ordinary generic drugs enter the era of low profits, high-end preparations and innovative drugs have become the key research and development direction
of pharmaceutical companies.
Among them, high-end preparations have higher technical threshold and more growth; Compared with the original research, it is favored
for reasons such as clinical time, R&D difficulty, and R&D cost.
It is reported that with the rapid development of high-end preparation technology, many high-end new preparation products
such as aripiprazole oral dissolving film, paclitaxel liposome, leuprorelin microspheres, salbutamol sulfate controlled-release tablets, ibuprofen suspension and so on have emerged.
In the context of the pharmaceutical industry accelerating its efforts to high-end new preparations, in order to meet higher pharmaceutical requirements, it is conceivable that many places and even pharmaceutical companies are accelerating the establishment of new high-end preparation R&D industrial
parks.
At present, in fact, many domestic pharmaceutical companies, including Qilu Pharmaceutical and Ruihua Pharmaceutical, have continued to increase R&D investment in the field of new high-end preparations, and have gradually built a series of preparation R&D and production platforms to accelerate the transformation
of scientific research achievements.
On September 13 this year, the "High-end Preparation Industrialization Base Project" invested and constructed by Shanghai Huiyong Pharmaceutical announced the start of construction; On September 9, Saito Biotech announced that the total amount of funds to be raised will not exceed 262 million yuan (including the principal amount), and the net funds raised after deducting the issuance expenses will all be used for high-end preparation industrialization projects
.
It is worth noting that in January 2022, the Ministry of Industry and Information Technology and other nine departments jointly issued the "14th Five-Year Plan" for the development of the pharmaceutical industry, which clearly stated that it is necessary to strengthen the research of key core technologies, improve the level of industrialization technology, support enterprises to integrate scientific and technological resources, and implement key pharmaceutical industrialization technology research projects
.
For chemical drug technology, we focus on complex preparation technologies with high selectivity and long-term sustained and controlled release, including injections such as microspheres, oral preparations such as sustained and controlled release, multi-particle systems, transdermal, implantation, inhalation, oral film drug delivery systems, drug and device combination products and other fields
.
Analysts believe that with the help of policies, high-end preparation technology will become an important breakthrough point in China's pharmaceutical innovation, and it will also become one of the
important directions for local pharmaceutical companies to participate in global innovation.
It is worth noting that at the same time, the industry expects that the upstream equipment industry will usher in new opportunities, and companies with strength will usher in benefits
.
It is reported that at present, some domestic head pharmaceutical machine enterprises have actually begun to undertake benefits, for example, Dongfulong has become the general contractor service provider of purification engineering of Shanghai Huiyong Pharmaceutical High-end Preparation Industrialization Base Project, and is also the core equipment supplier
of its cytotoxic filling production line, isolator and hormone filling production line and isolator injection workshop.
In general, as the pharmaceutical industry accelerates innovation, the high-end preparation industry will also embark on the "fast lane" of development, generating more and higher demand
for high-end pharmaceutical equipment.
This will also bring more opportunities and challenges
to the drug delivery machine industry.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.